BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 07 2021 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced
that the compensation committee of BioCryst’s board of directors
granted 10 newly-hired employees inducement options to purchase an
aggregate of 240,500 shares of BioCryst common stock on December
31, 2020 as inducements material to each employee entering into
employment with BioCryst. The options were granted in accordance
with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $7.45
per share, which is equal to the closing price of BioCryst common
stock on the grant date. The options vest in four equal annual
installments beginning on the one-year anniversary of the grant
date, in each case subject to the new employee’s continued service
with the company. Each stock option has a 10-year term and is
subject to the terms and conditions of BioCryst’s Inducement Equity
Incentive Plan and a stock option agreement covering the grant.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral,
small-molecule medicines that treat rare diseases in which
significant unmet medical needs exist and an enzyme plays a key
role in the biological pathway of the disease. Oral, once-daily
ORLADEYO™ (berotralstat) is approved in the United States for the
prevention of HAE attacks in adults and pediatric patients 12 years
and older, and under regulatory review for approval in Japan and
the European Union. BioCryst has several ongoing development
programs including BCX9930, an oral Factor D inhibitor for the
treatment of complement-mediated diseases, BCX9250, an ALK-2
inhibitor for the treatment of fibrodysplasia ossificans
progressiva, and galidesivir, a potential treatment for Marburg
virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a
viral neuraminidase inhibitor for the treatment of influenza, has
received regulatory approval in the U.S., Canada, Australia, Japan,
Taiwan and Korea. Post-marketing commitments for RAPIVAB are
ongoing. For more information, please visit the Company’s website
at www.biocryst.com.
BCRXW
Investor Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
Media Contact:Catherine Collier Kyroulis+1 917
886 5586ckyroulis@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2023 to Apr 2024